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Pathogens adhere to the host cells during the ﬁrst steps of infection through multivalent interactions which
involve protein–glycan recognition. Multivalent interactions are also involved at diﬀerent stages of immune
response. Insights into these multivalent interactions generate a way to use suitable carbohydrate ligands
that are attached to a basic scaﬀold consisting of e.g., dendrimer, polymer, nanoparticle, etc., with a
suitable linker. Thus a multivalent architecture can be obtained with controllable spatial and topology
parameters which can interfere with pathogen adhesion. Multivalent glycoconjugates bearing natural or
unnatural carbohydrate antigen epitopes have also been used as carbohydrate based vaccines to
stimulate an innate and adaptive immune response. Designing and synthesizing an eﬃcient multivalent
architecture with optimal ligand density and a suitable linker is a challenging task. This review presents a
concise report on the endeavors to potentially use multi- and polyvalent glycoconjugates as vaccines as
well as anti-infectious and anti-inﬂammatory drug candidates.1. Introduction
Multi- and polyvalency play a crucial role in various biological
processes like self-organization of matter, cell–cell recognition
leading to signal transduction, detection, and immune
response.1 Interactions between an m-valent receptor and an n-
valent ligand (m, n > 1; also m s n) are considered to be
multivalent interactions. The term polyvalency is especially
used in the context of ligands binding to receptors on interfaces
such as cell membranes, which oﬀer a large number (n » 10) of
two-dimensionally distributed binding sites.1 The surface of a
cell is covered with various carbohydrates which are usually
attached to other biomolecules like proteins or lipids. Diﬀerent
pathogens like bacteria, fungi, viruses, toxins, etc., adhere to the
host cells through multivalent interactions between carbohy-
drates and proteins as a rst step in the infection process. The
individual interactions between proteins and carbohydrates are
weak but multiple simultaneous interactions lead to strong
functionally useful avidities. The term avidity is dened in
biochemistry as the accumulated strength of the multiple
aﬃnities of individual non-covalent binding interactions.
Avidity was originally introduced to describe the binding
behavior of immunoglobulins with diﬀerent (multi) valencies
(antibodies, IgD, IgEm, and IgG monomers: divalent; IgA
homodimer: tetravalent; IgM homopentamer: decavalent).2 The
recent advent of carbohydrate microarray technologies3,4 as well
as advances in glycobiology and glycochemistry have paved the
way for insights into these multivalent interactions. This newie und Biochemie, Takustrasse 3, 14195
erlin.de
862–878knowledge about protein–glycan interactions between patho-
gens and mammalian host cells has made multivalent glyco-
conjugates attractive scaﬀolds for targeting diﬀerent pathogens.
Therefore, several unnatural glycoconjugates with diﬀerent
valencies and the spatial arrangement of ligands based on
scaﬀolds like proteins,5–7 polymers,8–10 fullerenes,11,12 calixar-
enes,13–15 dendrimers,16–20 nanoparticles,21,22 etc., have been
reported. The anti-adhesive or cell targeting properties of these
multivalent glycoconjugates can competitively inhibit the
pathogens from adhering to the host cells which ideally would
prevent or treat the disease caused by these pathogens. For
example, a synthetic glycolipid Gb3 (a-D-Gal(1,4)b-D-Gal(1,4) b-D-
Glc(1,O-ceramide)) analog that was covalently attached to
insoluble silica particle has emerged as an anti-adhesive
carbohydrate-based drug candidate for adsorbing shiga-like
toxins of E. coli. This synthetic analog of the Shiga toxin (Stx)
receptor (Synsorb Pk) is currently undergoing clinical trials.23
Furthermore, it has been found that surface sugar densities, as
well as the length and nature of the linker used for conjugation
to the basic scaﬀold, play a signicant role in the optimum
avidities and selectivities. Therefore, designing an eﬃcient
multivalent glycoconjugate remains a challenging task.24,25
Advances in the identication and synthesis of glycan epitopes
on diﬀerent pathogens have made carbohydrates attractive
vaccine targets and immunomodulators. The structurally
dened glycoconjugates displaying these unique glycan antigen
structures can follow a lectin-mediated cellular uptake mecha-
nism to generate an immune defense mechanism in the body
against chronic infections. In spite of the existing challenges in
the isolation and identication of the carbohydrate antigen




























































































View Article Onlineepitopes, a fruitful eﬀort has been made in this area and a
number of conjugate versions of polysaccharides vaccines are
now commercially available or in clinical trials.26 An octavalent
O-polysaccharide (OPS) with toxin A conjugate, for example, has
been found to be immunogenic and clinically eﬀective against
Pseudomonas aeruginosa and is currently undergoing phase III
clinical trials.27
This review is a concise overview on the diﬀerent attempts to
apply multivalent glycoconjugates as drugs in pathological
conditions like infections or cancer. It highlights the eﬀorts
being made by various research groups to design multivalent
glycoconjugates that can be used to inhibit the adhesion of
bacteria, bacterial toxins, and viruses to the host cells or to
stimulate the immune systems against pathogens like HIV. The
endeavor to apply multivalent glycoconjugates as anti-inam-
matory drugs by targeting leukocyte traﬃcking will also be
discussed.
2. Vaccines
The unique glycocalyx and its dense surface distribution on
diﬀerent pathogens and malignant cells have made carbohy-
drates attractive vaccine targets. Glycan antigens are diverse and
range from capsular polysaccharides to small monosaccharide
antigens. Capsular polysaccharides have been in use for
decades for providing immunity against diﬀerent bacterial
infections. The main bottleneck in the development of a
carbohydrate vaccine, however, is to identify carbohydrate
antigen itself. In recent years, the identication and synthesis of
the unique glycan epitope present on the various pathogens and
malignant cells has been more eﬃcient. This has paved a way
for the development of carbohydrate-based vaccines for elicit-
ing the immune response to the diﬀerent infections and cancer
as well. Another obstacle associated with the development of
carbohydrate-based vaccines is the poor antibody response to
carbohydrates which is usually due to the T-cell independent
immune responses triggered by repetitive carbohydrate anti-
gens.28,29 Carbohydrate specic antibodies have a low aﬃnity
with dissociation constants in the micromolar range and glycan
interactions mainly rely on the avidity eﬀects of multivalent
interactions. Avery and Goebel reported that immunogenicity of
carbohydrates can be increased by covalent attachment of
glycan to a suitable immunogenic protein which has led to the
discovery of conjugate vaccines.30 In the carbohydrate-based
vaccines glycan antigens are conjugated with a source of helper
T-cell epitope, usually with an immunogenic carrier protein.
Taxoids, metalloproteins like keyhole limpet haemocyanin
(KLH) or virus capsids are also used as carriers.31 Several strat-
egies can be used for linking the carrier to the sugar but one
needs to carefully investigate the immunogenicity of these
linkers to the glycan antigens.32,33 Adjuvants are also included in
the vaccine to increase the immunogenic response to antigens
and/or modulates it towards the desired immune responses.
Advantages of adjuvants include the reduction of the antigen
amount needed for a successful immunization, the reduction of
the frequency of booster immunizations needed, and an
improved immune response in elderly and immunoThis journal is © The Royal Society of Chemistry 2014compromised patients. Adjuvants include, for example, mineral
salts, oil emulsions, surfactant based formulations, microbial
derivatives, and particulate adjuvants (virosomes). With a few
exceptions, alum (potassium aluminium sulfate) is still the only
adjuvant that has been approved for human use in the majority
of countries worldwide.34 Therefore, it is found in numerous
vaccines, including diphtheria–tetanus–pertussis, human
papillomavirus, and hepatitis vaccines.35 QS-21, a saponin
derived from the tree bark of Quillaja saponaria, is also being
clinically tested.31 Tripalmitoyl-S-glyceryl-cysteinylserine
(Pam3Cys) has also been discovered to have adjuvant properties.
Fig. 1 depicts some of the diﬀerent strategies for preparing
glycoconjugate vaccines, i.e., multivalent synthetic conjugates,
protein conjugates, and lipid conjugates.312.1. Multivalent glycoconjugate vaccines against diﬀerent
pathogens
A diverse and dense array of protective capsular and lipopoly-
saccharides is present on the surface of bacterial pathogens.
Heterogeneity and complexity of the capsular polysaccharides
on bacterial pathogens have always been a great challenge in
the development of multivalent carbohydrate-based vaccines.
For example, more than 90 serotypes are known for S. pneu-
monia. The rst polysaccharide based vaccine, Pneumo Vax
from Merck and Co. launched in 1984 was composed of
unconjugated capsular polysaccharide isolated from 14 pneu-
monia serotypes; the current development provides active
immunization against 23 serotypes.36,37 In order to develop a
multivalent conjugate vaccine against diﬀerent bacterial path-
ogens, polysaccharides are generally isolated from most clini-
cally relevant serotypes and then degraded into smaller
products for activation and conjugation to immunogenic carrier
proteins. For example, Prevnar from Wyeth/Pzer is a heptava-
lent pneumococcal conjugate.
While developing the synthetic carbohydrate-based vaccines,
the eﬀect of chain length and saccharide density on the potent
antibody response can be addressed. For example, conjugates
with diﬀerent saccharide densities of tetra-, octa-, dodeca-, and
hexadecasaccharides were prepared for vaccine against S. dys-
enteriae. These conjugates were based on a tetrasaccharide
repeat unit of O-specic oligosaccharides. In the process it was
found that octa-, dodeca-, and hexadecasaccharides were
immunogenic and that the chain length determined the
optimal loading densities of saccharides.38 Furthermore, the
nonreducing end of Shigella dysenteriae type 1 O-specic oligo-
saccharides had an eﬀect on their immunogenicity as conju-
gates in mice.39 For many bacterial infections, multivalent
glycoconjugate vaccines have been developed based on the
fragments of their capsular polysaccharides. Examples include
Streptococcus pneumoniae, Neisseria meningitides, and Haemo-
philus inuenza.32 Table 1 shows some examples of commer-
cially available multivalent glycoconjugate vaccines.
Infection by parasitic protozoans and helminths is still a big
threat to the human population. Over 15 million deaths occur
worldwide per year due to parasitic infections and diseases,40
and no commercial vaccine has been developed as yet for any ofMed. Chem. Commun., 2014, 5, 862–878 | 863
Fig. 1 Diﬀerent categories of glycoconjugate vaccines. (a) Active glycan unit is conjugated to synthetic multivalent scaﬀolds, for example,
dendron or regioselectively addressable functionalized template, and made immunogenic by conjugation with a helper T-cell epitope. (b)
Activated glycan unit or the polyvalent glycan scaﬀold is conjugated with the immunogenic carrier protein. (c) Lipid conjugates can be prepared




























































































View Article Onlinethe parasitic infections like malaria, leishmaniasis, African
trypanosomiasis, amoebiasis, schistosomiasis, and lymphatic
lariasis. This is due to the complex immune evasion mecha-
nisms used by the diﬀerent parasites41 and to the lack of
understanding of molecular interactions between host immune
cells and parasites.42 The unique glycan antigens are abundant
and accessible on the surface of the multiple developmentalTable 1 Some commercially available multivalent glycoconjugate vaccin
Vaccine
Pneumococcal vaccine, polyvalent
Pneumococcal 7-valent conjugate (Diphtheria CRM197 protein)
Pneumococcal 13-valent conjugate (Diphtheria CRM197 protein)
Meningococcal (groups A, C, Y, and W-135) oligosaccharide
diphtheria CRM197 conjugate
Meningococcal (groups C and Y and Haemophilus b)
tetanus toxoid conjugate
Meningococcal (groups A, C, Y and W-135) polysaccharide
diphtheria toxoid conjugate
Meningococcal polysaccharide vaccine, groups A, C, Y and
W-135 combined
a The information in the table has been taken from a complete list of vac
which is available from the US Food and Drug Administration website (h
ucm093833.htm). CRM197 is a nontoxic mutant of diphtheria toxin.
864 | Med. Chem. Commun., 2014, 5, 862–878stages of diﬀerent parasitic protozoans and helminthes which
makes glycans attractive vaccine targets. Diﬃculties in obtain-
ing enough parasitic material for study also limit the progress in
this area. Several eﬀorts are, however, being made to investigate
potential vaccine antigens using advanced diagnostic tech-
niques for glycan detection and chemical or chemo-enzymatic
methods.43 Diﬀerent surface glycans, for example, associatedesa
Manufacturer (trade name)
Merck & Co, Inc. (Pneumovax 23)
Wyeth Pharmaceuticals Inc. (Prevnar)
Wyeth Pharmaceuticals Inc.
Novartis Vaccines and Diagnostics, Inc. (Menveo)
GlaxoSmithKline Biologicals (MenHibrix)
Sano Pasteur, Inc. (Menactra)
Sano Pasteur, Inc. (Menomune-A/C/Y/W-135)
cines licensed for immunization and distribution in the United States,
ttp://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/




























































































View Article Onlinewith Schistosoma spp. and Leishmania spp. have been identied
and are being evaluated as immunogens.31,42,44
It is known that each type of parasitic protozoa produces its
own unique and highly complex glycan structure. African
trypanosomes, for example, keep genetically switching their
highly immunogenic glycosylphosphatidylinositol (GPI)-
anchored surface glycoprotein which is called variant surface
glycoprotein (VSG).45 Virtually all protozoans, including Plas-
modium parasites that cause malaria synthesize GPI. The GPI
synthesized by Plasmodium may be a novel target for vaccine
production. Preclinical studies reported by Seeberger and
coworkers showed that a synthetic version of GPI conjugated to
keyhole limpet haemocyanin (KLH) (Fig. 2) elicited high titres of
immunoglobulin-g (IgG) and appeared to reduce the pathology
of malaria.46 Although the survival rates in mouse models
increased, further infection could not be prevented.47
The same group also presented a versatile approach based
on a synthetic GPI glycan array to correlate anti-GPI antibody
levels and protection from severe malaria but the question
remains whether an antitoxic immune response to malarial GPI
provides protection against malaria.48
Some glycoconjugate biosynthetic studies done on Leish-
mania protozoans have revealed that they also generate a
surface lipophosphoglycan (LPG) with unique phosphodiesters
of mannose in the backbone and furanosyl galactoside modi-
cations that might be contained within ether based phos-
pholipids, GPI-anchored glycoproteins, mucin-type membrane,
and secreted glycoproteins.44,49–51 The recent automated
syntheses of Leishmania related and other antigenic glycans
reported by Seeberger and coworkers will give a tremendous
boost to the generation of libraries of conjugate vaccine
candidates for screening.52
2.2. HIV vaccine development and challenges
The dense conserved cluster of oligomannose glycans on the
envelop glycoprotein, gp120 subunit of HumanFig. 2 Synthetic Plasmodium: glycosylphosphatidylinositol-keyhole
limpet haemocyanin (GPI-KLH).46
This journal is © The Royal Society of Chemistry 2014Immunodeciency Virus type 1 (HIV-1), masks conserved
protein epitopes and facilitates virus entry via interaction with
glycan binding proteins on susceptible host cells. The broadly
neutralizing monoclonal antibody 2G12 neutralizes a wide
range of HIV-1 strains in animal models by specically binding
to the cluster of oligomannose glycans on gp120.53–56 New
broadly neutralizing antibodies that also recognize and pene-
trate HIV glycan shield have recently been isolated from
patients.57 Highly dense clusters of oligomannose on gp120 are
stabilized by a network of intermolecular hydrogen bonding
and thus led to a close spacing between the carbohydrates
which is unusual in mammalian glycoproteins. These observa-
tions provide the basis for immunological discrimination by
2G12.58 Using the information available by structural and
modeling studies on how 2G12 interacts within the oligo-
mannose clusters of gp120,59 eﬀorts have been made to design
an immunogen that elicits 2G12 like antibodies.54 This is a very
challenging task due to the unique recognition mode of 2G12.
Several multivalent oligomannoside ligands containing
Mana(1,2)Man, including GlcNAcMan9 for 2G12, have been
synthesized for mimicking the densely conserved oligomannose
clusters in the glycan shield on gp120. The synthetic tetra-
mannoside (Man4) corresponding to the D1 arm of GlcNAcMan9
was found to be theminimum recognitionmotif and as eﬀective
as GlcNAcMan9 itself in binding to gp120.55 Synthetic strategies
for the multivalent presentation of oligomannose have involved
the use of oligodendrons, Qb bacteriophage, and generation of
cyclic glycopeptides60–63 (Fig. 3). A synthetic Man4 on bovine
serum albumin (BSA) molecule by Burton and coworkers,64 and
a cyclic glycopeptides conjugate of GlcNAcMan9, further conju-
gated with Outer Membrane Protein Complex (OMPC) by Dani-
shefsky and coworkers,65,66 could be used to induce a 2G12 like
antibody response, but antibodies did not bind to the gp120. In
another study by Geng and coworkers,67 a mutant strain of
Saccharomyces cerevisiae containing a large number and high
density of N-linked glycans elicited gp120 cross-reactive anti-
bodies in rabbit, but these antibodies did not neutralize HIV. The
current challenge lies in breaking the immune tolerance against
HIV-1 strains by eliciting the antibodies with proper specicity.
This is due to an inappropriate mimicry of the glycan shield
(exible glycans) and the unique architecture of the current
model antibody, 2G12. Moreover, there is a need for more
fundamental studies on B cell immunology to break the immune
tolerance towards the HIV-1 carbohydrate antigens.2.3. Cancer vaccine
Tumor associated carbohydrate antigens (TACAs) are over-
expressed self glycans in cancer cells which occur because of the
altered glycosylation.69 There is more glycosyltransferase
expression in cancer cells than in normal tissues which leads to
an increase in the size and branching of N-glycans, as well as to
more sialylation,70,71 and linking terminal residues to glycans
which results in an overexpression of certain terminal glycan
epitopes on tumors, such as sialyl Lewis X, sialyl Lewis A, sialyl
2-6-a-N-acetylgalactosamine (sTn), sialyl Lewis Y, globo-hex-
aosylceramide, and PSA.72–74 Although TACAs may potentiallyMed. Chem. Commun., 2014, 5, 862–878 | 865
Fig. 3 (a) GlcNAc2Man9 divalent glycopeptides outer membrane protein complex (OMPC) fromNeisseria meningitidis.66 (b) Man9, glycodendron




























































































View Article Onlineserve as vaccine antigens, they are poorly immunogenic and it is
diﬃcult to isolate the unique TACA glycan structure from
natural sources. A common way to break tolerance towards
TACAs is to use a monovalent carbohydrate antigen in multiple
copies on an immunogenic carrier such as KLH in the presence
of a strong adjuvant like QS21. This strategy describes the rst
generation monomeric cancer vaccine. Investigations on
antigen conjugates have established that KLH and QS21 are the
most potent carrier and adjuvant pair for breaking tolerance
towards TACAs. There are several studies where natural (glyco-
sphingolipid containing sialic acids like GD2, GD3, GM2, and
fucosyl GM1) and unnatural or synthetic (N-propionylated PSA,
GD2- and GD3-lactone, globohexaosylceramide and Lewis Y)
carbohydrate antigens that have been conjugated with KLH in
the presence of QS21 have been found to be immunogenic in
cancer patients.75–81 A novel approach to break the immuno-
tolerance to TACAs is to combine cell glycoengineering with
vaccines prepared using unnatural TACAs.82 The critical step in
this new strategy is metabolic engineering of cancer, namely, to
induce expression of an articial form of a TACA by supplying
tumors with an articial monosaccharide precursor. For this
purpose, tumor cells were incubated with diﬀerent N-acyl-D-
mannosamines, and modied forms of GM3 expressed on
tumor cells were analyzed by ow cytometry using antigen-
specic antisera. Recent reports by Guo and coworkers showed
that tumor cells expressed unnatural GM3 analog, i.e.,
GM3NPhAc instead of natural GM3 when incubated in the
presence of N-phenylacetyl-D-mannosamine.83 The GM3NPhAc–
protein conjugates are particularly immunogenic and produce
strong T-cell dependent antibodies. Therefore, the new glyco-
engineered melanoma cells expressing unnatural GM3NPhAc
were selectively killed by GM3NPhAc-specic antibodies
produced by GM3NPhAc–KLH conjugates.84 These results
suggest the feasibility of selectively eradicating cancer in vivo
without aﬀecting the normal cells. This immunotherapy may be
applicable to other tumors as long as they express GM3.866 | Med. Chem. Commun., 2014, 5, 862–878The development of multivalent vaccines85,86 has been
encouraged by the heterogeneity of TACA expression on
malignant cells. Danishefsky and coworkers87 have prepared
pentavalent and hexavalent carbohydrate antigenic constructs
on a single peptide backbone, conjugated with KLH and
Pam3Cys. The early immunogenicity studies in mice showed
that pentavalent unimolecular conjugates (on KLH or Pam3Cys)
were much more immunogenic than the corresponding pool of
monomeric KLH conjugates (Fig. 4). Recent clinical studies,
however, showed that lower IgM and IgG antibodies titres were
produced against individual antigens in high risk patients who
had been immunized with hexavalent vaccines including GM2,
Globo H, Lewis Y, glycosylated MUC-1-32mer, Tn, and TF. These
vaccines were prepared in a clustered formation, conjugated to
KLH, and mixed with QS-21.88 Mucin type glycans such as a-N-
acetyl-D-galactosamine (aGalNAc, the Tn antigen glycan) are
overexpressed on the surface of breast cancer cells. Cameron
and coworkers89 have recently reported the preparation of Tn-
glycan antigen-based glycopolymers which were conjugated to
gold nanoparticles and yielded ‘multicopy multivalent’ glyco-
nanoparticles with a size range of 5–25 nm. These glyco-
conjugated gold nanoparticles produced a strong and long-
lasting production of antibodies that were selective to the Tn-
antigen glycan and cross-reactive towards mucin proteins dis-
playing Tn.3. Multivalent glycoconjugates as
antiviral compounds
Multivalent binding interactions between glycoproteins on the
surface of diﬀerent pathogens and cellular receptors/oligosac-
charides play a crucial role in the initial stages of cellular
infection. For example, Fig. 5 shows how the multivalent
interactions between hemagglutinin glycoproteins on inuenza
virus and sialic acid residues on cells lead to endocytosis andThis journal is © The Royal Society of Chemistry 2014
Fig. 4 Structure of uimolecular pentavalent vaccine.87





























































































View Article Onlinethen infection. In the recent past, multivalent glycoconjugates
on dendritic/globular or linear scaﬀolds have emerged as potent
inhibitors of infection by diﬀerent viruses like HIV-1, Ebola,
inuenza, etc., which will be discussed in the following sections
by focusing on the most relevant studies.3.1. DC-SIGN mediated infection inhibition
Dendritic cells on mucosal surfaces carry a calcium dependent
(C-type) lectin that is a dendritic cell-specic intercellular
adhesion molecule (ICAM 3) grabbing non-integrin (DC-SIGN).
This lectin can bind to a broad spectrum of pathogens: viruses
(HIV-1, HIV-2, SIV, Ebola virus, hepatitis C virus, cytomegalo-
virus and dengue virus), bacteria (Mycobacterium tuberculosis,
Helicobacter pylori and Klebsiella pneumonia), yeasts (Candida
albicans), and parasites (Leishmania and Schistosoma).90 The
carbohydrate recognition domain (CRD) of DC-SIGN recognizes
the highly mannosylated and fucosylated glycoproteins which
are found on the surface of certain pathogens. For example,
highly mannosylated glycan shields on gp120 of HIV-1 are
specically recognized by DC-SIGN of dendritic cells onThis journal is © The Royal Society of Chemistry 2014mucosal surfaces. The HIV-1 virus is taken by these dendritic
cells to the lymph nodes where they eﬀectively transfer the virus
by a so-called trans infection of T-lymphocytes where the viral
replication occurs. Multivalent glycoconjugate systems have
been designed to mimic the surface of the virus to compete with
natural ligands for binding with receptors for the development
of carbohydrate-based antiviral drugs against HIV and Ebola
virus infections. Recent investigations by Bernardi, Clerici, and
coworkers have shown that a tetravalent dendron with four
copies of linear trimannoside inhibits DC-SIGN mediated trans
HIV infection process of CD4+ T lymphocytes in the presence of
elevated viral loads in cellular and cervical explants models
(Fig. 6).91,92 They found that multivalent presentation of linear
di- and trimannosides on G3 Boltron-type dendrimers (32
copies) strongly inhibited the cell infection by Ebola pseudo-
typed viral particles by blocking DC-SIGN receptor showing IC50
values in the nanomolar range (Fig. 6).93 In an another eﬀort to
mimic dense mannose clusters on HIV-1 envelop, Penades and
coworkers prepared a series of gold nanoparticles with diﬀerent
spacers and diﬀerent densities of oligomannoside. The manno-
GNPs containing the disaccharide Mana1-2Mana were found toMed. Chem. Commun., 2014, 5, 862–878 | 867
Fig. 6 (a) Tetravalent linear trimannoside conjugate for HIV infection
inhibition.92 (b) Trimannoside conjugates of G3 Boltorn type den-




























































































View Article Onlinebe the best inhibitors, because they increase inhibition 20 000-
fold (100% inhibition at 115 nM) compared to the corre-
sponding monomeric disaccharide (100% inhibition at
2.2 mM).94 Furthermore, these multivalent manno–glyco nano-
particles inhibited DC-SIGN-mediated HIV-1 trans-infection of
human T cells at nanomolar concentrations in experimental
setting that mimicked the natural route of virus transmission.953.2. Inuenza virus inhibition
Inuenza viral infection is one of the biggest challenges for
medicinal science and a big threat to the human population. It
oen causes epidemics and pandemics. Three glycoproteins
present on the virus surface, i.e., neuraminidase (NA), M2 ion
channel protein, and hemagglutinin (HA) are important targets
for ghting inuenza. HA glycoprotein is trimeric and most
abundant (600 copies per virus particle) on the surface of
inuenza virus.96 There is no multivalent drug available till now
which can target HA glycoprotein. The two glycoproteins HA
and NA determine the viral subtype. Commercially available
unimolecular drugs target either NA (zanamivir/Relenza, Osel-
tamivir/Tamiu) or M2 ion channel protein (amantadine and
rimantadine) activity. However, the emergence of stable and
transmissible drug-resistant inuenza strains can render these
drugs ineﬀective. The three-dimensional structure of HA com-
plexed with SA reported by Wiley and coworkers96 led to the
discovery that HA glycoproteins on the inuenza virus play a
signicant role in adhering virus to the susceptible cells in a
multivalent interaction between three sialic acid binding sites
on its globular domain with sialyloligosaccharide moieties of
cellular glycoconjugates. Therefore, macromolecular scaﬀolds868 | Med. Chem. Commun., 2014, 5, 862–878bearing multiple copies of sialic acid residues can be of great
use for a competitive inhibition of the virus attachment to the
cells. Eﬀorts are in progress for the design, synthesis, and
investigation of such multivalent glycoconjugates which may
lead to the discovery of anti-inuenza drugs.
So far the synthetic HA inhibitors mainly consisted of low
molecular weight scaﬀolds that form clusters of mono-,97,98 bi-,99
tetra-,100 and octavalent sialosides.101 The octavalent sialosides
were based on the polyazido-calix[4]arene scaﬀold but they
showed only a moderate glycoside cluster eﬀect and minimum
inhibitory concentration in the millimolar range. Both natural
and synthetic multivalent carriers have been explored to
prepare multivalent sialosides conjugate. Natural carriers
include the usage of self-assembling sialo-glycopeptides,102
proteins (specically equine a2-macroglobulin and guinea pig
a2-macroglobulin),100 and polysaccharides.103 Synthetic carriers
that have been typically used are spherical macromolecules like
dendrimers104 and liposomes,105 linear polymers,106 and nano-
structures.105 Sialylglycopolymers have been studied the most in
detail. Whitesides and coworkers have extensively studied a-
sialoside-polyacrylamide copolymers to inhibit the agglutina-
tion of erythrocytes by inuenza A virus. The best copolymer in
the series inhibited hemagglutination 104 to 105 times more
strongly than did similar concentrations of a-methyl sialo-
side.107 They also prepared C-glycoside by coupling amino-
sialosides with preactivated esters, i.e., poly[N-(acryoyloxy)
succinimide] (pNAS).108 Using the C-glycoside of sialic acid
made it possible to investigate hemagglutinin inhibition at
diﬀerent temperatures from 4–36 C because C-glycosides
cannot be hydrolyzed by the neuraminidase glycoproteins
present on inuenza virus. Extensive studies were performed to
optimize sialylglycopolymers by varying the chemical structure
and content of the ligand in the polymer and by altering the
structure of the side chains in the carrier which has led to
inhibitors with inhibitory concentrations in the nanomolar
range and were thousand-fold more eﬀective than the most
potent natural inhibitor, equine a2-macroglobulin. These
polymeric sialosides were quite eﬀective but they failed to
become drugs due to the severe toxicity of their polyacrylamide
backbone. Whiteside and coworkers only tested these polymeric
inhibitors for a single inuenza virus strain X31. Other groups,
however, observed a signicant variation in the sensitivity of
these inhibitors when tested against diﬀerent virus strains.109
Haag and coworkers chemically functionalized gold nano-
particles sized between 2 nm and 14 nm with sialic acid-
terminated glycerol dendron. The 14 nm sialic acid conjugated
AuNPs were nontoxic to cells and had a high aﬃnity for HA on
the inuenza virus surface as observed by electron microscopy
techniques and biochemical analysis (Fig. 7).110 The infection
inhibition amounted to 30% which led to the hypothesis that
virus-sized particles could further improve the inhibition of the
infection.111 Recently, Haag and coworkers investigated a new
class of biocompatible dendritic multivalent sialo conjugates
based on appropriately functionalized polyglycerol nanogels
(nPG) which were varied in size between 40–100 nm, respec-
tively (Fig. 8). The size and ligand density on the nanoparticles
were optimized, whereby the 50 nm sized sialic acid conjugatedThis journal is © The Royal Society of Chemistry 2014
Fig. 7 (a) Synthesis of sialic acid functionalized gold nanoparticles
(AuNPs). (b) Electron microscopic visualization of 14 nm sized AuNPs




























































































View Article OnlinenPG with only 12% ligand density was found to be the best
conjugate showing 80% inhibition of the inuenza virus A virus
(strainA/X31).112 Chen and coworkers recently reported that
poly-L-glutamine conjugated with multiple copies of drug
zanamivir (PGN-ZA) via a exible linker inhibited inuenza viral
fusion and release at subnM concentrations of zanamivir.113
These PGN-ZA polymers were still eﬀective against isolated ZA-
and oseltamivir-resistant inuenza virus.114Fig. 8 Sialic acid functionalized polyglycerol nanogels (nPG) with hemag
chemically cross-linked dendritic polyglycerol (dPG) units.
This journal is © The Royal Society of Chemistry 20144. Antibacterials
Bacteria and bacterial toxins infect host cells via multivalent
interactions involving protein–glycan recognition in the rst
steps of infection. Bacteria constitute a large domain of
prokaryotic microorganisms which can be typically a few
micrometers in length, whereas bacterial toxins are small
poisonous substances secreted by living bacteria during expo-
nential growth. Millions of deaths per year are caused by shiga
and cholera toxin infections. Both these toxins belong to the
clinically signicant subset of bacterial AB5 toxins, where A
subunit is enzymatically cleavable and B5 homopentamer has
receptors for oligosaccharide recognition on the cellular
surface. Fig. 9 shows, for example, an inhibited cellular uptake
of a pentameric bacterial toxin by a sugar-conjugated pentacy-
clen core. Bundle and co-workers designed and improved some
oligovalent, water soluble carbohydrate ligands called “Starsh”
and “Daisy” to inhibit Shiga toxin (Stx) 1 and Stx2 which were
generated by E. coli strains. The inhibition potential was
conrmed with in vivo experiments.115,24 Multivalent glyco-
conjugates based on diﬀerent scaﬀolds like pentacyclen, den-
drimers, polymers, fullerenes, cyclodextrins, cyclopeptides, and
gold nanoparticles have been developed which can interfere
with the pathogen (bacteria or bacterial toxin) adhesion
process.116 However, the resulting sugar density at the glyco-
conjugate surface as well as the chemical structure of the linker
groups are important factors for an eﬀective inhibitor.20 To
determine the corresponding partner for the glycan-binding
protein (GBP) of the pathogenic microorganisms, glycan
microarrays were also developed to scan a great number of
glycan candidates in a short time.4,25,117 The combination of
active glycans covalently linked to various carrier platforms
resulted in powerful compounds which should be able to treat
infectious diseases. These multivalent glycoconjugates may play
a role in ghting antibiotic resistant bacteria strains as well.1184.1. Cholera toxin inhibition
Cholera is an intestinal infection caused by the cholera toxin
(CT) produced from Vibrio cholera119,120 results in fastglutinin receptors on the virus surface. The nPG consists of a number of
Med. Chem. Commun., 2014, 5, 862–878 | 869
Fig. 9 Inhibition of the cellular uptake of a pentameric bacterial toxin by a sugar-conjugated pentacyclen core. (a) Cellular uptake of a pen-
tameric bacterial toxin. The whole toxin binds to cellular receptor, followed by endocytosis. (b) Inhibition of a toxin binding to cellular receptors




























































































View Article Onlinedehydration and shock caused by watery diarrhea. The seven
cholera pandemics over the past 185 years aﬀected nearly the
whole world. Cholera deaths are still common in remote areas
where eﬀective treatment is unavailable.121 Conjugative-plasmid
mediated multiply antibiotic-resistant (including to tetracy-
cline) V. cholerae O1 (MARV) has also emerged as a major
problem, rst in Tanzania then in Bangladesh. Antibiotic
strains that are resistant to tetracycline, ampicillin, kanamycin,
streptomycin, sulphonamides, trimethoprim, and gentamicin
have appeared in several cholera endemic countries during the
past two decades.121
CT belongs to a family of bacterial AB5 toxins with an enzy-
matically active A subunit which is uptaken by the mammalian
cells via an oligosaccharide recognition of the B5 subunit. CT's
rst mode of action is to strongly bind to the receptor cells on
the cell surface. The receptor for the CT is a specic glycolipid,
the ganglioside GM1, a regular component in the outer leaet of
many cell membranes. The A subunit is connected to the B-
pentamer via a disulde bridge. Aer cellular uptake, the A
subunit is activated and released in the cytosol by reduction of
the disulde bond.24,122,123 Several multivalent glycoconjugates
have been explored to target the B5 subunit of cholera toxin to
prevent its cellular uptake.
Diﬀerent multivalent glycoconjugates, bearing pseudo-
trisaccharides and four to eight oligo-GM1 units, have been
prepared based on calixarenes, poly(propylene imine), and
PAMAM dendrimers. The B5 pentamer unit of CT had a much
higher aﬃnity for these conjugates than native GM1.124–126
Pieters and coworkers synthesized multivalent versions of the
GM1os using glycodendrimers using the click chemistry
approach. These multivalent versions strongly inhibited the
CTB5-subunit. For example, the most complex multivalent
GM1os conjugate, which was an octavalent glycodendrimer, was
380 000-foldmore potent with IC50¼ 50 pM than themonovalent
GM1-mimic127 (Fig. 10). This GM1-mimic was compared with870 | Med. Chem. Commun., 2014, 5, 862–878natural GM1 gangliosides and showed a similar binding to the
CTB5-subunit in an ELISA-type assay.128 Multivalent galactose
inhibitors were prepared as simplied versions of multivalent
GM1 derivatives. Multivalent binding interactions compensated
the low binding aﬃnity of galactose for CTB5-subunit. Tetrava-
lent and octavalent galactose inhibitors with long spacer arms,
for example, competed well with natural GM1os.129
Fan and coworkers explored a series of multivalent ligands
based on diﬀerent glycoside moieties with linkers of various
lengths for CT inhibition. In the rst approach, a semi-rigid
pentacyclen core was used to bind 5 copies of m-nitrophenyl-a-
D-galactoside (MNPG) via a semiexible linker. The MNPG unit
represents the active nger which can be bound to the CT
receptor. The monovalent MNPG nger showed 100-fold greater
inhibition in comparison to the weaker binding monovalent
galactose nger. In terms of multivalency, the pentavalent
MNPG ligand exhibited a 260-fold better aﬃnity enhancement
(IC50 ¼ 0.9 mM) in comparison to the monovalent MNPG
nger.130 The second approach involved the design of branched
multivalent ligands with 5-fold symmetry. The branched biva-
lent galactose ligands were attached to the pentacyclen core via
exible arms which led to branched decavalent conjugates. A
million-fold improvement in inhibition power (IC50 ¼ 0.04 mM)
was observed with the best branched decavalent ligand with a
repeating unit of the linker n ¼ 4 in comparison to the mono-
valent galactose. The compound with a lower number of linker
units showed less inhibition aﬃnity. DLS studies proved that
the bivalent ligand can complex the CT in a 1 : 2 manner. The
results of Fan and coworkers showed that the rational design of
these multivalent ligand and their linker size is very important
for CT inhibition131 (Fig. 11).
Richards and coworkers examined several glycopolymers
based on a poly(pentauorophenyl methacrylate) precursor
with varying saccharide density, linker length, and chain length
due to a 1,3 dipolar cycloaddition. Compounds with a longerThis journal is © The Royal Society of Chemistry 2014




























































































View Article Onlinelinker length showed higher CT inhibition. Polymers with the
highest and lowest sugar density (100% and 10%) showed the
highest activity, which demonstrates the complexity of the gly-
coconjugate design for CT inhibition.1324.2. Escherichia coli (E. coli) inhibition
E. coli is a Gram-negative bacterium that easily adheres to the
target cells in the urinary tract through a mannose-binding lectin
FimH. The FimH lectin is located at the tip of type 1 mbriae,
also called pili, which are the most abundant structures on the
surface of Gram-negative bacteria. The uropathogenic E. coli
strains can bind to the carbohydrate receptors in the urinary tract
through FimH, colonize, and then cause bladder infections. This
bacterial adhesion can be prevented by competitive mannosidic
inhibitors. Eﬀective inhibitions have been shown by compounds
with terminal a-D-mannosyl residues.133–135
Lindhorst and coworkers developed various saccharide
modied nanodiamond (ND) conjugates to detect and remove
E. coli bacteria from aqueous solutions. The surface of the
thermally annealed ND was functionalized via a Diels–AlderFig. 11 Multivalent (single and branched) galactose binders for CT.130,131
This journal is © The Royal Society of Chemistry 2014cycloaddition of the p-bonds on the diamond surface (dien-
ophil) and an in situ generated o-quinodimethane (diene). The
covalently arylated ND can easily be sulfonated and the sulfonic
acid groups can be subsequently partially reduced to target thiol
groups for more exible functionalization of the ND.136 These
modied NDs were used as platforms and were conjugated via a
“thiol–ene reaction” with diﬀerent monosaccharides.
These NDs are also applied to inhibit biolm formation on
biotic surfaces or medical devices due to E. coli attachment.
These biolms result in an increasing source of infections in
clinical settings. Barras and coworkers developed ND that were
modied with mannose moieties via an azide–alkyne Huisgen
cycloaddition. These multivalent glycol–nanodiamonds can
inhibit the E. coli type 1 mbriae-mediated adhesion to
eukaryotic cells (T24 bladder cells) and reduce the E. coli biolm
formation.137
A second carbon-based platform inhibiting pathogens with a
lower valency is provided by multivalent fullerenes.138 Vincent
and co-workers developed “fullerene sugar balls” with twelve
mannose moieties per fullerene. Diﬀerent sugar units were




























































































View Article Onlinecycloaddition to achieve a C60 core which was completely sur-
rounded by sugar residues.12 Durka and coworkers used this
method to couple twelve mannose moieties with diﬀerent linker
lengths to the fullerene core to inhibit the FimH of E. coli. The
aﬃnity of the mannoside fullerenes to the FimH was determined
by ITC and SPR. Those experiments showed that the increased
distance between the active mannose moieties and the C60 core
can considerably improve the binding aﬃnity to FimH. However,
the nanomolar aﬃnity values were measured for both methods.
The mannoside fullerene had a benzylic aromatic ring at the
anomeric position of the sugar as well as an amide group in the
linker structure, which seems to be benecial for lectin binding139
and can accommodate up to seven FimH molecules.140
A third class of glycoconjugates which can inhibit E. coli
bacteria are multivalent sugar functionalized pillar[5]arenes.
Nierengarten and coworkers developed a pillar[5]arene glyco-
cluster with ten peripheral acetylated mannosyl groups via a 1,3
dipolar cycloaddition. The nal product, which is a promising
compound for FimH inhibition, was achieved by deacetylation.
The inhibition capacity was determined in a hemagglutination
inhibition assay. The assay determines the concentration of the
glycoconjugate, which is necessary to prevent adhesion of uro-
pathogenic E. coli with guinea pig's red blood cells. The inhi-
bition titre was in a low mM range (5.91 mM).141
Huang and coworkers used a similar approach and “clicked”
galactose groups (hydrophilic compartment) and alkyl chains
(hydrophobic compartment) via an azide–alkyne Huisgen
cycloaddition to a pillar[5]arene core. Self-assembled nanotubes
were formed in water due to van der Waals interactions of the
hydrophobic and hydrophilic parts of the glycoconjugate and
intermolecular hydrogen bonds aer one week. TEM and SEM
measurements as well as uorescence microscopy conrmed the
structure. Furthermore, TEM and uorescence microscopeFig. 12 Preparation of three multivalent glycocluster via copper-catalyz
inhibit the LPS heptosyl-transferase WaaC.148
872 | Med. Chem. Commun., 2014, 5, 862–878measurements exhibited a high agglutination rate of the multi-
valent nanotubes with E. coli, which conrms the high aﬃnity of
these glycoconjugates to the pathogenic bacteria.142 The length
of the self-assemblies here also played a key role in the formation
of bacterial clusters and was a crucial factor in controlling
agglutination. Because the self-assembled nanotubes were
several micrometers long, they could interconnect more bacteria,
which resulted in an enhanced agglutination ability.
Other scaﬀolds of multivalent glycoconjugates which can
inhibit E. coli were also established. Gouin and co-workers
designed heptavalent glycoconjugates where n-heptyl a-D-man-
noside was covalently linked to b-cyclodextrin core via a “click”
procedure. 2 mg of the multivalent FimH antagonist instilled in
the mouse bladder signicantly reduced the urinary tract
infection.143 Furthermore, recent advances in functional
supramolecular/polymeric structures like bigger nanogels, gra-
phene sheets, micrometer sized bres, etc. could be promising
scaﬀolds for eﬀective inhibition of large bacteria particles.144
4.3. Inhibition of the lipopolysaccharide synthesis
Lipopolysaccharides (LPS) are thermostable compounds that
protect and stabilize the bacterial membrane can be divided
into three parts. The core region of LPS consists of oligosac-
charides with a 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) and
two L-glycero-a-D-manno-heptose (heptose) units in the inner
core and hexoses in the outer core.145 E. coli with only a few
heptose units are signicantly more permeable to certain
hydrophobic antibiotics.146 The inhibition of the heptose
biosynthetic pathway is just one approach which can be used to
circumvent the conventional methods of targeting the bacterial
receptors.147
Vincent and coworkers developed some multivalent glyco-
sylated fullerenes that can inhibit the LPS heptosyltransferaseed 1,3 dipolar cycloaddition with a series of fullerene hexa-adducts to




























































































View Article OnlineWaaC. This glycotransferase catalyzes the incorporation of the
rst L-heptose into LPS. A series of fullerene hexa-adducts with
12 copies of peripheral sugar units displaying the mannopyr-
anose core structure of bacterial L,D-heptosides was synthesized
via a copper-catalyzed 1,3 dipolar cycloaddition (Fig. 12). The
inhibition of WaaC was determined by an assay whichmeasures
the IC50 values of ADP-2-heptose. The multivalent fullerene
glycoconjugate of 1, 2, and 3 showed an inhibition potential in a
low micromolar range (IC50 ¼ 11; 47 and 6.7 mM). The mono-
meric glycosides, on the other hand, displayed IC50 values above
400 mM. Another eﬀect of the “fullerene sugar balls” is that the
inhibition data evaluated on a “per-sugar” basis showed an
increase of the multivalent single glycosides in comparison to
the monovalent ones.148
5. Anti-inﬂammatory drugs
The recruitment of circulating leukocytes is crucial at the sites
of inammatory diseases including hypersensitivity reaction as
well as autoimmune diseases. The leukocyte recruitment from
the bloodstream occurs through a multistep process in which
the leukocytes captured on the endothelium, roll along, and
interact with the endothelium in postcapilary venules.1 The
transmigration of the leukocytes through the vessel wall and
further migration into the extracellular tissue takes place
subsequently. Leukocyte migration is initiated by interactions
between E-, L-, and P-selectins (cell adhesion molecules) and
their associated carbohydrate ligands. L-selectin is expressed by
the most leukocytes. E-selectin and P-selectin are expressed by
inammed endothelia cells. However, P-selectin is also
expressed by activated platelets. One approach for an anti-
inammatory therapy is to target the leukocyte traﬃcking.
Therefore multivalent glycoconjugate systems have been
developed that mimic the naturally occurring SLexa ligands and
inhibit the selectin-moieties.149–151
Patton and coworkers developed a series of multivalent
polylysine conjugates to inhibit the interactions of E-selectin.
The polylysine was conjugated with tetrasaccharide Lewis X and
showed a highly active E-selectin inhibition and reduced the
neutrophil rolling on activated endothelia cells with IC50 values
in the nanomolar range. Furthermore, the increased size of the
multivalent molecule as well as the ligand loading (35% and
50%) at the surface yielded the best inhibition data and a 700-
fold increase in inhibition compared to the monovalent
compound.152 Haag and coworkers synthesized several multi-
valent glyco-conjugates to inhibit L- and P-selectin binding.153
These functionalized galactose moieties were then coupled to a
dentritic polyglycerol (dPG) scaﬀold via a 1,3 dipolar cycload-
dition. The inhibition rate of the multivalent compound was
compared to a tetravalent one based on a pentaerythritol core.
The multivalent glycoconjugates showed a signicant increase
in the inhibition of L- and P-selectin binding compared to the
tetravalent ones. The multivalent compound with the sulfated
sugar moieties exhibited the highest inhibition rate.153 These
studies were expanded and other carbohydrates were coupled to
the PE and dPG cores. The multivalent dPG-conjugates with
sulfated sugar-moieties showed the best inhibition results withThis journal is © The Royal Society of Chemistry 2014IC50 values in the high picomolar to the low nanomolar range
and conrmed the previous results.154 Other scaﬀolds of multi-
valent glycoconjugates which can inhibit L-selectin binding were
also established. A series of multivalent polyacrylamide-based
conjugates155 as well as some neoglycopolymers156 conrms the
multivalent eﬀect. Furthermore, Haag and coworkers demon-
strated that single dendritic polyglycerol sulfates (lacking the
sugar unit) are also excellent candidates to inhibit L-, P-selectin
binding and damp inammation in vivo.151
6. Conclusion
In this article we have reviewed the current applications of
multivalent glycoconjugates for a diverse set of diseases and
discussed the challenges involved and endeavors made to
address them. The development of multivalent glycoconjugate
based vaccines has been fruitful, and a number of carbohydrate-
based vaccines for various bacterial infections are already
commercially available or under clinical trial. Vaccines against
Shigella dysenteriae, Streptococcus pneumoniae, Neisseria menin-
gitides, and Haemophilus inuenza are commercial examples.
However, signicant issues remain to be addressed. Develop-
ment of vaccines against parasitic infections is still a big chal-
lenge due to the lack of understanding of complex immune
evasion mechanisms used by diﬀerent parasites. The key diﬃ-
culty in developing HIV vaccines is mimicking the complex,
dense cluster of glycans that are capable of eliciting neutralizing
antibodies, specically against HIV. On the other hand,
researchers have been successful in identifying tumor associated
carbohydrate antigens (TACAs) and then using them in multi-
valent forms, along with immunogenic carrier proteins, like
keyhole limpet haemocyanin (KLH) to elicit strong T-cell
dependent antibodies. Several synthetic antigen candidates have
reached clinical trials, although more precise criteria for their
eﬃcacy and clinical impact remain to be dened. Besides using
carbohydrates as vaccines, several multivalent glycoconjugates
with controlled topology and valency have been explored to better
understand multivalency, and their potential as anti-infectious
agents for several viral and bacterial infections has been
demonstrated in multiple examples. However, very few
approaches consider biocompatible scaﬀolds in the appropriate
dimension of the biological pathogen for the most eﬀective
shielding. Developing compatible polyvalent glycoconjugates
with strong binding and infection inhibition eﬃciencies to reach
the market as drugs still remains a challenging goal.
AbbreviationADP-2-heptose Adenosine diphosphate-2-heptose
Alum Potassium aluminium sulfate
AuNPs Gold nanoparticles
BSA Bovine serum albumin
CRD Carbohydrate recognition domain
CD4+ Cluster of diﬀerentiation 4+
CT Cholera toxin




























































































View Article OnlineDC-SIGN874 | Med. Chem. CDendritic Cell-Specic Intercellular adhesion
molecule-3-Grabbing Non-integrindPG Dendritic polyglycerol
E. coli Escherichia coli
E-, L-, and P-
selectinsEndothelial-, leukocytes-, and platelets-







HIV Human immune deciency virus type
ITC Isothermal titration calorimetry
ICAM 3 Intercellular adhesion molecule 3
IC50 Half maximal inhibitory concentration















QS21 Quillaja saponaria 21
S. pneumonia Streptococcus pneumoniae
S. dysenteriae Shigella dysenteriae
sTn Sialyl 2-6-a-N-acetylgalactosamine
SA Sialic acid
SIV Simian immunodeciency viruses
Stx Shigatoxin
SEM Scanning electron microscope
SLex Sialyl Lewis x




TEM Transmission electron microscopy
TACAs Tumor associated carbohydrate antigens
VSG Variant surface glycoproteinAcknowledgements
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